Candel Therapeutics, Inc. filings document a clinical-stage oncology company developing multimodal biological immunotherapies and reporting as a Nasdaq-listed issuer of common stock. Its proxy materials cover director elections, auditor ratification and annual-meeting voting matters, while Form 8-K reports furnish operating and financial results and research-and-development presentations.
Other filings disclose material agreements and capital-structure matters, including term-loan financing and facility lease amendments, along with clinical and regulatory disclosures tied to aglatimagene besadenovec and linoserpaturev. The filing record also reflects governance matters, shareholder voting mechanics and exhibit-based disclosures for key corporate actions.
Candel Therapeutics director Renee Gaeta received a grant of 32,000 stock options to buy common shares at an exercise price of $9.08. These options were awarded as compensation, not through open-market trading.
The options use time-based vesting and become exercisable on the earlier of June 23, 2027 or the company’s next Annual Meeting of Stockholders, with vesting stopping if she leaves the board unless the board decides otherwise. The options expire on June 23, 2036, and following this grant she holds 32,000 options directly.
Candel Therapeutics director Gary J. Nabel received a grant of stock options covering 32,000 shares of common stock. The options have an exercise price of $9.08 per share and expire on June 23, 2036. These options are subject to time-based vesting and will vest and become exercisable on the earlier of June 23, 2027 or the date of the company’s next annual meeting of stockholders. Vesting stops if he ceases serving on the board, unless the board determines that vesting should continue.
Candel Therapeutics director Diem Nguyen received a stock option grant for 32,000 shares of common stock. The options have an exercise price of $9.0800 per share and expire on June 23, 2036. They vest upon the earlier of June 23, 2027 or the company’s next annual stockholder meeting, so long as Nguyen continues serving on the board.
Candel Therapeutics director Paul B. Manning received a grant of stock options covering 32,000 shares of common stock. The options have an exercise price of $9.08 per share and expire on June 23, 2036. Following this award, he holds 32,000 stock options directly.
The option is subject to time-based vesting. The underlying shares vest and become exercisable on the earlier of June 23, 2027 or the date of the next Annual Meeting of Stockholders, and vesting stops if he leaves the board unless the board determines otherwise.
Candel Therapeutics, Inc. reported the results of its Annual Meeting of Stockholders held on June 23, 2026. As of April 24, 2026, there were 73,270,239 outstanding shares of voting common stock entitled to vote at the meeting.
Stockholders elected four Class II directors to serve until the 2029 annual meeting: Edward J. Benz, Jr., M.D., Paul B. Manning, Maha Radhakrishnan, M.D., and Paul Peter Tak, M.D., Ph.D., FMedSci. Support ranged from 24,897,348 to 31,591,618 votes "for," with broker non-votes of 22,175,525 for each nominee.
Stockholders also ratified the appointment of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 53,543,020 votes for, 238,508 against, and 87,967 abstentions. No other matters were submitted for a vote.
Candel Therapeutics approved a new employment agreement with Chief Financial Officer Charles Schoch, confirming his at-will role and compensation structure. He will continue to receive an annual base salary of $468,600 and remains eligible for an annual bonus targeted at 40% of base salary, plus standard employee benefits.
If the company terminates him without cause or he resigns for good reason, and he signs a separation agreement, he is entitled to nine months of base salary plus his target annual bonus, paid over nine months, and continued company-paid health insurance contributions for up to nine months, subject to COBRA and other conditions. If such a termination occurs within one month before or 12 months after a change in control, all of his time-based equity awards will fully vest. The agreement also includes customary confidentiality, non-competition and non-solicitation provisions.
Candel Therapeutics reported extended follow-up results from its pivotal phase 3 trial of aglatimagene besadenovec (CAN-2409) in intermediate- to high-risk localized prostate cancer. In 745 patients, adding aglatimagene to standard radiotherapy improved prostate cancer–specific disease-free survival by 39% versus placebo (hazard ratio 0.61; 95% CI 0.44–0.85; p=0.0031) after a median 58‑month follow-up.
In the 635‑patient intermediate‑risk subgroup, prostate cancer–specific disease-free survival improved by 41% (hazard ratio 0.59; 95% CI 0.41–0.84; p=0.0034). Trends favored aglatimagene for time to biochemical failure, time to metastasis, and time to new anticancer therapy, with very low metastatic rates in the intermediate‑risk arm.
The regimen was generally well tolerated, with mostly mild to moderate, short‑lived systemic symptoms and similar rates of serious adverse events and treatment discontinuations versus placebo. Candel plans to submit a Biologics License Application for CAN‑2409 in localized prostate cancer in the fourth quarter of 2026.
Candel Therapeutics reports that RTW Investments and Roderick Wong beneficially own 6,422,018 shares of Common Stock, representing 8.8% of the class. The filing states the percentage is calculated using 73,246,927 Shares outstanding as of March 5, 2026.
The statement is a Schedule 13G joint filing by RTW Investments, LP and Roderick Wong, M.D., reporting shared voting and dispositive power over the 6,422,018 shares held by RTW Funds.
Candel Therapeutics reported a net loss of $8.9 million for the three months ended March 31, 2026, compared with net income of $7.4 million a year earlier. The shift was driven by higher research and development spending of $9.8 million and general and administrative expenses of $6.4 million, reflecting expanded clinical and commercial-readiness activities.
Cash and cash equivalents rose to $194.8 million, up from $119.7 million at year-end 2025, primarily due to a February 2026 follow-on equity offering that raised $100 million in gross proceeds and $93.5 million in net proceeds. The company also has a $50.0 million term loan outstanding under its Trinity facility and an accumulated deficit of $239.2 million. Management expects existing resources to fund operations for at least 12 months. Candel continues to advance its viral immunotherapy pipeline, highlighted by positive phase 3 data for aglatimagene in localized prostate cancer and plans to file a Biologics License Application in late 2026.
Candel Therapeutics reported a first quarter 2026 net loss of $8.9 million, reversing from net income of $7.4 million a year earlier, mainly due to higher operating expenses and a smaller gain from warrant revaluation. Research and development expenses rose to $9.8 million from $4.0 million, and general and administrative expenses increased to $6.4 million from $4.1 million, reflecting clinical, manufacturing, and commercial readiness spending for aglatimagene.
Candel strengthened its balance sheet, with cash and cash equivalents rising to $194.8 million as of March 31, 2026 from $119.7 million at year-end, helped by issuing 18.3 million shares for roughly $100 million in gross proceeds and a separate $100 million royalty funding agreement. The company expects this cash to fund operations into Q1 2028.
Strategically, Candel plans to submit a Biologics License Application for aglatimagene in localized, intermediate- to high-risk prostate cancer in Q4 2026, initiate a pivotal phase 3 trial in metastatic non-small cell lung cancer in June 2026, and has secured a U.S. commercialization partnership with EVERSANA to support a potential launch.